Company: LGN
Filing Date: 2025-02-14
Form Type: DRS
Source: 0000950123-25-002471
Chunk: 108

Company: Legence Corp.
Filing Date: 2025-02-14
Form: DRS
Chunk 108
---
 and the Class A Common Stock issued in this offering. The noncontrolling interest owners own shares of Class B Common Stock. These shares of          
 Class B Common Stock are not considered participating securities because they have no right to receive dividends or a distribution on liquidation or winding up of Legence, and no earnings are allocable to such class. Accordingly, basic and 
 diluted earnings per share of Class B Common Stock has not been presented. The table below presents the computation of pro forma basic and dilutive loss per share for Legence (in thousands, except per share amounts):                        |

|                                                                       |     | Year Ended        
 December 31, 2024 |
|:----------------------------------------------------------------------|:----|:------------------|
| Numerator:                                                            |     |                   |
| Net loss                                                              |     | $                 |
| Net loss attributable to noncontrolling interests                     |     |                   |
| Net loss attributable to Legence Corp.                                |     |                   |
| Denominator:                                                          |     |                   |
| Weighted average shares of Class A Common Stock outstanding (basic)   |     |                   |
| Incremental common shares attributable to dilutive instruments(1)     |     |                   |
| Assumed conversion of LGN Units to shares of Class A Common Stock(2)  |     |                   |
| Weighted average shares of Class A Common Stock outstanding (diluted) |     |                   |
| Basic loss per share                                                  |     | $                 |
| Diluted loss per share                                                |     | $                 |

72

Confidential Treatment Requested by Legence Corp.

Pursuant to 17 C.F.R. Section 200.83

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appear elsewhere in this prospectus. In addition to historical consolidated financial information, the following discussion contains “forward-looking statements” that reflect our future plans, estimates, beliefs and expected performance. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors” and elsewhere in this prospectus. Our actual results may differ materially from those contained in or implied by any forward-looking statements. We do not undertake any obligation to publicly update any forward-looking statements except as otherwise required by